Norbormide
Norbormide is a rodenticide that is specifically toxic to rats. It was discovered in the 1960s by scientists at the Shell Development Company in California. Norbormide is unique among rodenticides due to its selective toxicity towards rats, particularly the R. norvegicus species, while being relatively harmless to other animals.
Chemistry[edit]
Norbormide is a pharmacologically active N-acyl derivative of a bicyclic amine. Its chemical name is N-3,5-dinitrophenyl norbornanedicarboximide. The compound has a complex mode of action that is not fully understood, but it is known to cause vasoconstriction in rats, leading to their death.
Toxicity[edit]
The toxicity of norbormide is highly specific to rats. It is thought that this selectivity is due to a combination of factors, including the rat's specific metabolic pathways and the presence of a specific binding site in the rat's vascular smooth muscle cells. The lethal dose for rats is around 10 mg/kg, while the lethal dose for other animals is significantly higher.
Use and Regulation[edit]
Norbormide has been used as a rodenticide in various countries around the world. However, its use has been limited due to its relatively slow action and the fact that rats often avoid eating it. In the European Union, norbormide is not approved for use as a rodenticide due to concerns about its environmental impact.
Research[edit]
Research into norbormide is ongoing, with scientists seeking to understand its unique selectivity and to potentially develop new, more effective rodenticides based on its structure and mode of action.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
